Three Abstracts on Dosing Regimens of Cellectar’s CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO Annual Meeting Proceedings May 18, 2017
Cellectar Biosciences to Host Conference Call on May 11, 2017 to Report First Quarter 2017 Financial Results and Corporate Performance May 2, 2017
Cellectar’s Radiotherapeutic PDCs Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical Studies Apr 27, 2017
Cellectar Biosciences Receives Additional U.S. Patents for PDC Optical Agents in the Detection of Multiple Cancers Apr 25, 2017
UPDATED: Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer Apr 21, 2017
Cellectar Biosciences Receives Japanese Patent for CLR 131 and CLR 125 for the Treatment of Cancer Stem Cells Apr 18, 2017
Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer Apr 12, 2017
Cellectar Biosciences Adds Industry Veterans Douglas Swirsky and Frederick Driscoll to Its Board of Directors Apr 10, 2017
After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers Mar 30, 2017
